8.1 Ocular Drug Delivery Methods & Routes of Administration

Ocular Drug Delivery Methods & Routes of Administration

Therapeutic management of vitreoretinal disorders poses unique pharmacological challenges. The neurosensory retina, retinal pigment epithelium (RPE), and choroidal vasculature reside in an immune-privileged, highly protected compartment insulated from external environmental exposures and systemic fluctuations. Certified Retina Technicians must understand the distinct pharmacokinetic barriers governing ocular drug absorption, the rationales behind specialized delivery routes, and the clinical implications of vitreous clearance kinetics.

---

Anatomical and Physiological Barriers to Retinal Drug Delivery

Delivering therapeutic concentrations of pharmaceutical compounds to the posterior segment requires overcoming formidable static and dynamic anatomical barriers.

1. The Corneal Barrier

The cornea functions as the primary mechanical and chemical barrier to anterior drug absorption:

• Epithelium: Composed of 5 to 6 layers of non-keratinized stratified squamous cells joined by continuous apical zonula occludens (tight junctions). The epithelium is highly lipophilic, presenting a high electrical resistance barrier that excludes hydrophilic, charged, or macromolecular drugs.
• Stroma: Accounts for roughly 90% of total corneal thickness and consists of an organized, hydrated extracellular matrix of type I/V collagen and glycosaminoglycans. The stroma is hydrophilic and acts as a major barrier to highly lipophilic compounds.
• Endothelium: A single monolayer of hexagonal cells with macula adherens junctions. It is moderately lipophilic and regulates stromal deturgescence.

Because of this alternating "lipophilic-hydrophilic-lipophilic" sandwich structure, only small, moderately lipophilic molecules with balanced partition coefficients can penetrate the intact cornea. Even for optimized topical molecules, less than 1% to 5% enters the anterior chamber, and virtually none reaches the retina or vitreous.

2. The Blood-Ocular Barriers

The eye is shielded from systemic circulation by two principal barrier systems:

• Blood-Aqueous Barrier (BAB): Formed by tight junctions between non-pigmented ciliary epithelial cells and the non-fenestrated endothelial cells of iris blood vessels. The BAB restricts passage of plasma proteins and hydrophilic molecules into the anterior chamber aqueous humor.
• Blood-Retinal Barrier (BRB): A major physiologic barrier to posterior-segment drug delivery, comprising two distinct anatomic sites:
  1. Inner Blood-Retinal Barrier (iBRB): Composed of non-fenestrated endothelial cells of the retinal capillary microvasculature interconnected by extensive zonula occludens tight junctions, surrounded by pericytes and astrocyte foot processes. It prevents the passive diffusion of systemic macromolecules, polar molecules, and pathogens into the neurosensory retina.
  2. Outer Blood-Retinal Barrier (oBRB): Formed by tight junctions joining adjacent retinal pigment epithelial (RPE) cells. While the underlying choriocapillaris contains fenestrated capillaries that allow free transudation of fluid and solutes into the choroidal stroma, the oBRB tightly regulates all movement from the choroid into the subretinal space.

---

Topical Routes: Solutions, Suspensions, and Ointments

Tear Film Dynamics and Punctal Occlusion

The normal physiological volume of the preocular tear film is approximately 7 to 10 µL. In contrast, standard commercial ophthalmic eyedroppers deliver a droplet volume between 30 and 50 µL. Upon instillation of a single drop:

1. The conjunctival fornix transiently retains a maximum of approximately 30 µL without overflowing.
2. The remaining excess volume immediately spills over the lower eyelid margin onto the cheek or drains rapidly through the upper and lower lacrimal puncta.
3. Fluid entering the puncta travels through the canaliculi into the lacrimal sac and down the nasolacrimal duct, emptying into the inferior meatus of the nasal cavity.
4. The nasal mucosa possesses extensive, highly vascularized submucosal venous plexuses. Medications absorbed here bypass hepatic first-pass metabolism, passing directly into the internal jugular vein and systemic venous circulation.

To maximize ocular contact time and minimize potentially dangerous systemic absorption (e.g., beta-blockers or alpha-agonists), technicians must instruct patients in digital punctal occlusion: apply gentle, firm index finger pressure against the medial canthus over the lacrimal sac for 1 to 2 minutes while keeping the eyelids gently closed without blinking or squeezing.

Topical Formulations & Posterior Segment Limitations

• Solutions & Suspensions: Aqueous solutions dissolve completely; suspensions contain fine drug particles and are mixed only as directed by the product label; the required motion and duration vary. Because of tear turnover (roughly 16% per minute) and rapid nasolacrimal flushing, topical drug residence time on the cornea is less than 2 to 5 minutes, resulting in posterior segment bioavailability of <0.001%.
• Ophthalmic Ointments: Formulated in a mineral oil and petrolatum hydrocarbon base. Ointments melt at ocular physiological temperature, significantly prolonging precorneal contact time. However, ointments create an irregular optical film that causes marked, transient visual blurring, making them suitable primarily for bedtime (QHS) instillation. Ointments are strictly contraindicated if an open globe injury or full-thickness corneal laceration is suspected, as intraocular petrolatum entrapment induces severe granulomatous endophthalmitis.

---

Periocular Delivery: Subconjunctival and Posterior Sub-Tenon's Injections

Periocular routes deposit a pharmacologic depot adjacent to the sclera, bypassing the corneal epithelial barrier:

• Subconjunctival Injection: Delivers medication into the loose connective tissue beneath the bulbar conjunctiva. Drug diffuses across the sclera into the anterior segment and anterior ciliary body; commonly utilized for postoperative antibiotics, cycloplegics, or mid-dilating combinations.
• Posterior Sub-Tenon's Injection (PSTI): The needle or blunt cannula is advanced through the bulbar conjunctiva and Tenon's capsule into the posterior sub-Tenon's space, placing a depot (e.g., triamcinolone acetonide 40 mg/mL [Kenalog]) adjacent to the posterior sclera. Drug molecules undergo transscleral diffusion through hydrophilic scleral collagen pores into the choroid and retina.
• Clinical Risks of PSTI: Marked elevation of intraocular pressure (steroid response in up to 30% of patients), inadvertent globe perforation, retrobulbar hemorrhage, ptosis, and localized orbital fat atrophy with periocular skin depigmentation.

---

Intravitreal Injections & Vitreous Pharmacokinetics

Intravitreal injection (IVT) is the primary procedural intervention in modern vitreoretinal practice. Delivering pharmacologic agents directly into the vitreous cavity achieves immediate, high therapeutic concentrations at the target retina and choroid while circumventing both anterior corneal barriers and the blood-retinal barrier.

Pharmacokinetics in Phakic vs. Vitrectomized Eyes

In an untampered, non-vitrectomized eye, the vitreous body represents a transparent, viscoelastic hydrogel composed of 98% to 99% water structured within a delicate network of type II collagen fibrils and hyaluronic acid coils:

• Large macromolecular therapeutic proteins (e.g., bevacizumab [149 kDa], aflibercept [115 kDa], ranibizumab [48 kDa]) diffuse slowly through this gel matrix.
• Elimination occurs primarily via two pathways: anterior elimination through the posterior chamber and trabecular meshwork (Schlemm's canal), and posterior elimination via transretinal transport across the RPE.
• In non-vitrectomized eyes, the intravitreal half-life ($t_{1/2}$) of anti-VEGF monoclonal antibodies ranges from approximately 4 to 7 days, sustaining clinical biological suppression of intraocular VEGF for 4 to 12 weeks.

In eyes that have undergone pars plana vitrectomy (PPV), the viscoelastic vitreous gel is permanently replaced with low-viscosity aqueous fluid:

• Convective fluid currents within the vitreous cavity increase dramatically.
• Passive molecular diffusion is replaced by accelerated bulk fluid turnover.
• The intravitreal clearance of anti-VEGF agents and intraocular antibiotics is accelerated 2- to 3-fold, reducing the half-life of bevacizumab or ranibizumab to 1.5 to 2.5 days.
• Consequently, vitrectomized patients frequently require more frequent anti-VEGF injection intervals (e.g., every 4 weeks rather than extended intervals) to maintain disease stability in diabetic macular edema or neovascular age-related macular degeneration.

---

Sustained-Release Intraocular Implants & Delivery Systems

To mitigate the treatment burden of monthly or bimonthly intravitreal injections, sustained-release drug delivery systems have been developed to maintain therapeutic drug concentrations over extended intervals.

1. Biodegradable Polymer Implants: Ozurdex

• Mechanism: The Ozurdex implant contains 0.7 mg of dexamethasone micronized within a biodegradable poly(lactic-co-glycolic acid) (PLGA) polymer matrix.
• Kinetics: Administered into the vitreous cavity via a specialized 22-gauge pen-like applicator through the pars plana. As water penetrates the PLGA matrix, ester bonds undergo natural hydrolytic cleavage, releasing dexamethasone in a biphasic profile (initial therapeutic burst followed by continuous plateau release) over 4 to 6 months.
• Degradation: The PLGA polymer hydrolyzes entirely into endogenous lactic acid and glycolic acid, which are metabolized into carbon dioxide and water. The implant dissolves completely, requiring no surgical removal.
• Indications: Macular edema secondary to branch or central retinal vein occlusion (BRVO/CRVO), non-infectious posterior uveitis, and diabetic macular edema (DME).

2. Non-Biodegradable Reservoirs: Iluvien and Yutiq

• Mechanism: Iluvien (0.19 mg fluocinolone acetonide) and Yutiq (0.18 mg fluocinolone acetonide) are tiny, non-bioerodible cylindrical polyimide implants (3.5 mm in length, 0.37 mm diameter) injected via a 25-gauge applicator.
• Kinetics: Operates as a membrane-controlled reservoir releasing a steady, ultra-low microgram dose (~0.25 µg/day) of fluocinolone acetonide directly into the vitreous cavity for up to 36 months (3 years) following a single injection.
• Fate of Scaffold: Because the polyimide casing is non-biodegradable, the empty microscopic tube remains permanently inert within the inferior vitreous base.
• Complications: Important risks include cataract progression in phakic eyes and ocular hypertension or glaucoma. Frequency and management vary by implant, indication, follow-up duration, and patient factors, so use the current product label and clinician's monitoring plan rather than a universal percentage.

3. Port Delivery System (PDS, Susvimo)

• Architecture: A surgically placed, refillable intraocular reservoir implant anchored permanently in the sclera at the pars plana (superotemporal quadrant).
• Function: Features a silicone drug reservoir, a self-sealing septum accessible through the conjunctiva, and a porous titanium release-control element that facilitates continuous, passive diffusion of a customized, high-concentration formulation of ranibizumab (100 mg/mL) into the vitreous cavity over a 24-week period.
• Refill Procedure: Performed in an outpatient clinic setting under sterile conditions using a specialized double-lumen port delivery refill needle that simultaneously aspirates residual depleted fluid and injects fresh drug.
• Safety Profile & Monitoring: Requires close biomicroscopic surveillance for conjunctival erosion, wound retraction, endophthalmitis (which showed higher incidence in initial clinical trials compared to regular injections), vitreous hemorrhage, and implant displacement.

---

Systemic Administration in Posterior Segment Disease

Systemic administration (oral or intravenous) delivers drug molecules throughout the entire vascular tree, but penetration into the vitreous and retina is severely restricted by the tight junctions of the inner and outer blood-retinal barriers.

• Hydrophilic molecules and large proteins achieve vitreous concentrations that are less than 1% to 2% of corresponding serum levels.
• Therapeutic posterior segment concentrations can only be reached by administering high systemic doses, which frequently produces unacceptable systemic organ toxicity.
• Exceptions in Retina Practice:
  1. Oral Carbonic Anhydrase Inhibitors (Acetazolamide [Diamox]): Lipophilic properties and high oral bioavailability allow penetration across ocular barriers to treat acute post-injection IOP spikes or augment RPE fluid resorption in chronic cystoid macular edema.
  2. High-Dose Corticosteroids (Oral Prednisone, IV Methylprednisolone): Indicated for sight-threatening panuveitis, Vogt-Koyanagi-Harada (VKH) disease, sympathetic ophthalmia, and arteritic anterior ischemic optic neuropathy (Giant Cell Arteritis).
  3. Systemic Anti-infectives: High-dose intravenous antibiotics (vancomycin, ceftazidime) for endogenous endophthalmitis, or oral antivirals (valacyclovir) for acute retinal necrosis (ARN), where severe intraocular inflammation has pathologically disrupted the blood-retinal barrier, permitting passive transvascular drug entry.

---

Clinical Table: Ocular Drug Delivery Methods Comparison